Drug Trial Radar · NCT07464327
A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Mar 31, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Hansoh BioMedical R&D CompanyIndustry
- Sponsor type
- Industry
- First posted
- Mar 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, controlled phase III clinical study to evaluate the efficacy and safety of HS-20093 injection combined with adebrelimab versus docetaxel in previously treated patients with advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.
Conditions
- Non-Small Cell Lung Cancer
Interventions
HS-20093Drug
Participants will receive intravenous infusions of HS-20093 and adebrelimab: HS-20093 at a dose of 8.0 mg/kg every 3 weeks (Q3W) until disease progression or other treatment discontinuation criteria are met; adebrelimab at a dose of 1200 mg Q3W until disease progression or other treatment discontinuation criteria are met.
DocetaxelDrug
Participants will receive docetaxel at a dose of 75 mg/m² Q3W until disease progression or other treatment discontinuation criteria are met.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR)Time frame: Approximately 3 years after the fist patient with first dose
- Overall survival (OS)Time frame: Approximately 5 years after the fist patient with first dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.